S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
D000374:Aggression / Q000187:drug effects; D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004594:Electrophysiology; D006380:Helplessness, Learned; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009448:Neurochemistry; D010078:Oxazines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism; D050637:Receptors, Dopamine D3; D013395:Sucrose / Q000378:metabolism; D013550:Swimming; D014828:Vocalization, Animal / Q000187:drug effects
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D019208:Brain-Derived Neurotrophic Factor; C493593:DRD3 protein, human; D018491:Dopamine Agonists; C493594:Drd3 protein, mouse; C493595:Drd3 protein, rat; D007211:Indoles; D010078:Oxazines; D012333:RNA, Messenger; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C478818:S 32504; C046649:ropinirole; D013395:Sucrose